CA2073060A1 - Anticorps monoclonal specifique d'un epitope non-immunodominant des proteines du vih - Google Patents

Anticorps monoclonal specifique d'un epitope non-immunodominant des proteines du vih

Info

Publication number: CA2073060A1
Authority: CA; Canada
Prior art keywords: antibody; hiv; cells; binding; protein
Prior art date: 1990-01-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002073060A

Other languages

English (en)

Inventor

Paul J. Higgins

Charles F. Scott, Jr.

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Repligen Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-01-16

Filing date

1991-01-16

Publication date

1991-07-17

1991-01-16 Application filed by Individual filed Critical Individual

1991-07-17 Publication of CA2073060A1 publication Critical patent/CA2073060A1/fr

Status Abandoned legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title description 21
102000004169 proteins and genes Human genes 0.000 title description 19
230000027455 binding Effects 0.000 claims abstract description 30
210000002966 serum Anatomy 0.000 claims abstract description 22
101710091045 Envelope protein Proteins 0.000 claims abstract description 18
101710188315 Protein X Proteins 0.000 claims abstract description 18
102100021696 Syncytin-1 Human genes 0.000 claims abstract 6
239000003053 toxin Substances 0.000 claims description 16
231100000765 toxin Toxicity 0.000 claims description 16
239000002596 immunotoxin Substances 0.000 claims description 15
238000000034 method Methods 0.000 claims description 10
101710121417 Envelope glycoprotein Proteins 0.000 claims description 9
125000000539 amino acid group Chemical group 0.000 claims description 3
210000004027 cell Anatomy 0.000 description 55
241000725303 Human immunodeficiency virus Species 0.000 description 42
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 21
239000000427 antigen Substances 0.000 description 15
108700012359 toxins Proteins 0.000 description 15
108091007433 antigens Proteins 0.000 description 14
102000036639 antigens Human genes 0.000 description 14
101800001690 Transmembrane protein gp41 Proteins 0.000 description 9
239000012634 fragment Substances 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
230000003053 immunization Effects 0.000 description 7
101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 6
238000011282 treatment Methods 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
238000002649 immunization Methods 0.000 description 5
229940051026 immunotoxin Drugs 0.000 description 5
230000002637 immunotoxin Effects 0.000 description 5
231100000608 immunotoxin Toxicity 0.000 description 5
239000000463 material Substances 0.000 description 5
241000282412 Homo Species 0.000 description 4
150000001413 amino acids Chemical group 0.000 description 4
239000012636 effector Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010003445 Ascites Diseases 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
241000700605 Viruses Species 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
231100000599 cytotoxic agent Toxicity 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
239000002254 cytotoxic agent Substances 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
108700004025 env Genes Proteins 0.000 description 3
101150030339 env gene Proteins 0.000 description 3
238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
230000004927 fusion Effects 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
241000894007 species Species 0.000 description 3
239000000126 substance Substances 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
239000004971 Cross linker Substances 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
231100000167 toxic agent Toxicity 0.000 description 2
239000003440 toxic substance Substances 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000014616 translation Effects 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical group C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
101100427992 Azotobacter vinelandii usg gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000087624 Monoclona Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
AEKNYBWUEYNWMJ-QWOOXDRHSA-N Pramiconazole Chemical compound O=C1N(C(C)C)CCN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(CO3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 AEKNYBWUEYNWMJ-QWOOXDRHSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000003327 cancerostatic effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000009643 clonogenic assay Methods 0.000 description 1
231100000096 clonogenic assay Toxicity 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000009830 intercalation Methods 0.000 description 1
230000002687 intercalation Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000002523 lectin Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
108010010621 modeccin Proteins 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
230000007096 poisonous effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
-1 showing the gpl20 Proteins 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Photometry And Measurement Of Optical Pulse Characteristics (AREA)
Radiation Pyrometers (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA002073060A 1990-01-16 1991-01-16 Anticorps monoclonal specifique d'un epitope non-immunodominant des proteines du vih Abandoned CA2073060A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46503590A	1990-01-16	1990-01-16
US465,035		1990-01-16

Publications (1)

Publication Number	Publication Date
CA2073060A1 true CA2073060A1 (fr)	1991-07-17

Family

ID=23846250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002073060A Abandoned CA2073060A1 (fr)	1990-01-16	1991-01-16	Anticorps monoclonal specifique d'un epitope non-immunodominant des proteines du vih

Country Status (4)

Country	Link
EP (1)	EP0511300A4 (fr)
JP (1)	JPH05506142A (fr)
CA (1)	CA2073060A1 (fr)
WO (1)	WO1991010742A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0554401A4 (en) *	1990-10-26	1996-10-30	New York Health Res Inst	Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
US6797492B2 (en)	1991-05-17	2004-09-28	Merck & Co., Inc.	Method for reducing the immunogenicity of antibody variable domains
DE19809785C2 (de) *	1998-03-08	2000-02-10	Wolfgang Bergter	Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
US8481041B2 (en)	2005-04-06	2013-07-09	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
WO2007084692A2 (fr) *	2006-01-20	2007-07-26	Welson Pharmaceuticals, Inc.	Immunoconjugués pour le traitement de maladies infectieuses
CA2651285C (fr) *	2006-05-15	2014-08-19	Immunomedics, Inc.	Procedes et compositions de traitement d'infections par le virus de l'immunodeficience humaine avec des anticorps ou des fragments d'anticorps conjugues
EP3303370A4 (fr)	2015-05-28	2019-03-13	Immunomedics, Inc.	Produits de construction t20 pour thérapie et/ou vaccins anti-vih (virus de l'immunodéficience humaine)
CA3045756A1 (fr)	2015-12-05	2017-06-08	Centre Hospitalier Universitaire Vaudois	Agents de liaison au vih

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2437213A1 (fr) *	1978-09-28	1980-04-25	Cm Ind	Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4861707A (en) *	1987-02-02	1989-08-29	E. I. Du Pont De Nemours And Company	Human immunodeficiency virus antigen
WO1988005824A1 (fr) *	1987-02-02	1988-08-11	E.I. Du Pont De Nemours And Company	Selection d'anticorps monoclonaux contre des glycoproteines virales

1991
- 1991-01-16 JP JP91503590A patent/JPH05506142A/ja active Pending
- 1991-01-16 EP EP19910903736 patent/EP0511300A4/en not_active Withdrawn
- 1991-01-16 WO PCT/US1991/000319 patent/WO1991010742A1/fr not_active Application Discontinuation
- 1991-01-16 CA CA002073060A patent/CA2073060A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
JPH05506142A (ja)	1993-09-16
EP0511300A4 (en)	1993-05-26
WO1991010742A1 (fr)	1991-07-25
EP0511300A1 (fr)	1992-11-04

Publication	Publication Date	Title
US8110203B2 (en)	2012-02-07	Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes
US5922325A (en)	1999-07-13	Synergistic neutralization of HIV-1 by human monoclonal antibodies and other antibodies directed against the v3 loop and the CD-4 binding site of GP-120,and the use for immunotherapy of HIV-1 infection
EP0815125B1 (fr)	2004-06-30	RECEPTEUR gC1q, ZONE DE LIAISON DE gp120 DE VIH-1 A CE DERNIER, ET PEPTIDES ET ANTICORPS DE CIBLAGE ASSOCIES
CA1330038C (fr)	1994-06-07	Methode et compositions pour l'utilisation des polypeptides env de vih et anticorps diriges contre ces polypeptides
CA2102511A1 (fr)	1992-11-15	Anticorps heteroconjugues pour le traitement de l'infection a vih
PL155084B1 (en)	1991-10-31	A method of monoclonic antibodies generating and the useof theses antibodies in distributions based on immulogical affinity
EP0492560B1 (fr)	2001-10-10	Anticorps monoclonaux humains contre la glycoprotéine transmembranaire (gp41) de HIV-1, et peptides associés
US5266478A (en)	1993-11-30	Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
CA2073060A1 (fr)	1991-07-17	Anticorps monoclonal specifique d'un epitope non-immunodominant des proteines du vih
EP0478689A1 (fr)	1992-04-08	ANTICORPS MONOCLONAUX HUMAINS DE LA gp 120 DU VIH-1 MN?
US6083504A (en)	2000-07-04	Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1)
WO1993004693A1 (fr)	1993-03-18	Inhibition synergique du vih-1
AU2006200454B2 (en)	2008-05-08	Compositions and methods for treating viral infections
JP3364181B2 (ja)	2003-01-08	ヒト免疫不全ウイルスのエンベロープポリペプチドおよびその抗体
AU2006200455A1 (en)	2006-02-23	Compositions and methods for treating viral infections
GELDER	0	Patent 2268372 Summary
MXPA99003380A (en)	2000-12-06	Compositions and methods for treating viral infections
AU2004201321A1 (en)	2004-04-29	Compositions and methods for treating viral infections
AU2004208648A1 (en)	2004-09-30	Compositions and methods for treating infections

Legal Events

Date	Code	Title	Description
1995-07-16	FZDE	Dead